Taysha Gene Therapies Inc (TSHA) - Gross Profit Ratio

TSHA (Taysha Gene Therapies Inc) - company brandmark

Can gene therapy for Rett syndrome deliver sustainable profits? The annual gross margin chart illustrates efficiency trends, where the 79.20 mark characterizes this parameter. Taysha Gene Therapies (TSHA) is implementing green chemistry principles for the safe disposal of reagents. Taysha Gene Therapies (TSHA) is currently focusing on a single key drug, seeking a strategic partner among pharmaceutical behemoths to ensure its further survival.

TSHA (Taysha) Gross Margin history from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for Taysha Corp (TSHA)

- stock price and consensus target price:
- cash and cash flow statistics:
Basic company analysis:Taysha Gene Therapies, Inc. TSHA
Manufactured products of Taysha

Taysha Gene Therapies (TSHA) leverages its status as a pioneer in CNS gene therapy to monetize unique intellectual property, creating high added value for life-saving drugs. Gross margin measures the profit share after deducting direct production costs, reflecting the business's operational efficiency, which is clearly demonstrated by the gross margin history in the GURU.Markets analytical service for assessing the asset's investment attractiveness.

Direct competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|QURE: Gross Margin|Return on Gross Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Gross Margin|solidbio.com (SLDB) - Return on Sales by Gross Profit|Gross Profitability Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Gross Return on Sales|Benitec Biopharma - Return on Gross Profit|DSGN: Gross Return on Sales|RCKT: Return on Gross Profit|FDMT - Gross Margin|LXEO: Gross Margin|Korro Bio Inc. - Gross Profit Rate|EDIT (editasmedicine.com) - Gross Margin|Gross Profitability SLN|Gross Profitability ProQR Therapeutics NV (PRQR)|Codexis - Gross Return on Sales|Gross Profitability Sangamo SGMO|NAUT: Gross Return on Sales|MGX: Return on Gross Profit|Gross Profit Margin Precision BioSciences|GBIO (generationbio.com) - Return on Gross Profit|Gross Profit Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Gross Margin|Gross Return on Sales IMNN (Imunon, Inc.)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability